{"id":42782,"date":"2019-04-29T23:59:52","date_gmt":"2019-04-29T21:59:52","guid":{"rendered":"https:\/\/newserver.fyb.de\/immunic-therapeutics-first-nasdaq-listing\/"},"modified":"2019-04-29T23:59:52","modified_gmt":"2019-04-29T21:59:52","slug":"immunic-therapeutics-first-nasdaq-listing","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/","title":{"rendered":"Immunic Therapeutics: First NASDAQ listing"},"content":{"rendered":"<p>Lands\u00adhu\u00adt\u00ad\/\u00adPlan\u00adegg-Martins\u00adried\/ New York, April 17, 2019 \u2014 The Martins\u00adried-based biophar\u00admaceu\u00adti\u00adcal company <strong>Immu\u00adnic Thera\u00adpeu\u00adtics (\u201cImmu\u00adnic\u201d)<\/strong> has successfully made the leap to the NASDAQ tech\u00adno\u00adlogy exch\u00adange in a so-called <strong>reverse take\u00adover<\/strong>. This is the first time that a port\u00adfo\u00adlio company of <strong>Wachs\u00adtums\u00adfonds Bayern, mana\u00adged by Bayern<\/strong> <strong>Kapi\u00adtal<\/strong> <strong>,<\/strong> has succee\u00added in going public. Toge\u00adther with a consor\u00adtium of inves\u00adtors, Wachs\u00adtums\u00adfonds Bayern inves\u00adted in the company in 2016 as part of a Series A round, thus laying the finan\u00adcial foun\u00adda\u00adtion for the company\u2019s posi\u00adtive deve\u00adlo\u00adp\u00adment. The stock market listing is now expec\u00adted to provide Immu\u00adnic with finan\u00adcing secu\u00adrity for its further deve\u00adlo\u00adp\u00adment acti\u00advi\u00adties and thus unleash further growth momen\u00adtum. Simul\u00adta\u00adneously with the closing of the tran\u00adsac\u00adtion, Bayern Kapi\u00adtal and six other inves\u00adtors have again inves\u00adted a total of 26.7 million euros (around 30 million US dollars) in the former Bava\u00adrian start-up.<\/p>\n<p>Immu\u00adnic is a biotech company foun\u00added in 2016. The company\u2019s deve\u00adlo\u00adp\u00adment pipe\u00adline today includes selec\u00adtive, orally available immu\u00adno\u00adlogy thera\u00adpies for the treat\u00adment of chro\u00adnic inflamm\u00ada\u00adtory and auto\u00adim\u00admune dise\u00ada\u00adses such as ulce\u00adra\u00adtive coli\u00adtis, Crohn\u2019s dise\u00adase, relapsing-remit\u00adting multi\u00adple scle\u00adro\u00adsis and psoria\u00adsis. As part of a share exch\u00adange (so-called reverse take\u00adover) with the alre\u00adady listed company Vital Thera\u00adpies Inc. Immu\u00adnic has successfully made the step to the NASDAQ. The company\u2019s common stock, with the new common name of Immu\u00adnic Inc. have been traded on NASDAQ since April 15, 2019. The main objec\u00adtive of the newly formed company is to conti\u00adnue the deve\u00adlo\u00adp\u00adment of drugs for chro\u00adnic inflamm\u00ada\u00adtory and auto\u00adim\u00admune dise\u00ada\u00adses until they are ready for the market.<\/p>\n<p><strong>Dr. Daniel Vitt, CEO of Immu\u00adnic<\/strong>  AG, says: \u201cInves\u00adtors such as Bayern Kapi\u00adtal with the Bava\u00adrian Growth Fund have given us the oppor\u00adtu\u00adnity to form, deve\u00adlop and grow as an inde\u00adpen\u00addent company. The fact that we can now take advan\u00adtage of the oppor\u00adtu\u00adni\u00adties offe\u00adred by the capi\u00adtal market to enter the next phase of our corpo\u00adrate deve\u00adlo\u00adp\u00adment also has to do with the fact that we have been able to count on the contin\u00adued trust of our inves\u00adtors from the very beginning.\u201d<\/p>\n<p>Bava\u00adria\u2019s Minis\u00adter of Econo\u00admic Affairs, Hubert Aiwan\u00adger, on Immu\u00adnic\u2019s stock market listing: \u201cWe have endo\u00adwed the Bava\u00adrian Growth Fund with 100 million euros. The exam\u00adple of Immu\u00adnic shows that this money is well inves\u00adted. The market is open to inno\u00adva\u00adtive and well-mana\u00adged start-ups \u2014 even IPOs are possi\u00adble in a very short&nbsp;time.\u201d<\/p>\n<p><strong>About Immu\u00adnic,&nbsp;Inc.<\/strong><br>\nImmu\u00adnic, Inc. (Nasdaq: IMUX) is a clini\u00adcal-stage biophar\u00admaceu\u00adti\u00adcal company with a pipe\u00adline of selec\u00adtive, orally available immu\u00adno\u00adlogy thera\u00adpies for the treat\u00adment of chro\u00adnic inflamm\u00ada\u00adtory and auto\u00adim\u00admune dise\u00ada\u00adses, inclu\u00adding ulce\u00adra\u00adtive coli\u00adtis, Crohn\u2019s dise\u00adase, relapsing-remit\u00adting multi\u00adple scle\u00adro\u00adsis and psoria\u00adsis. The company is deve\u00adlo\u00adping three small mole\u00adcule products: IMU-838 is a selec\u00adtive immu\u00adno\u00admo\u00addu\u00adla\u00adtor that inhi\u00adbits intracel\u00adlu\u00adlar meta\u00adbo\u00adlism of acti\u00adva\u00adted immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of ROR\u03b3t; and IMU-856 targets resto\u00adra\u00adtion of intesti\u00adnal barrier func\u00adtion. Immu\u00adnic\u2019s most advan\u00adced deve\u00adlo\u00adp\u00adment program, IMU-838, is in Phase 2 clini\u00adcal trials for the treat\u00adment of ulce\u00adra\u00adtive coli\u00adtis and relapsing-remit\u00adting multi\u00adple scle\u00adro\u00adsis. Another Phase 2 trial in Crohn\u2019s dise\u00adase is plan\u00adned for 2019. An inves\u00adti\u00adga\u00adtor-initia\u00adted, proof-of-concept clini\u00adcal trial of IMU-838 in primary scle\u00adro\u00adsing cholang\u00adi\u00adtis is also plan\u00adned at Mayo Clinic. For more infor\u00adma\u00adtion: www.immunic-therapeutics.com.<\/p>\n<p><strong>About Bayern Kapital<\/strong><br>\nBayern Kapi\u00adtal GmbH, based in Lands\u00adhut, was foun\u00added in 1995 as a <strong>wholly owned subsi\u00addiary of LfA F\u00f6rder\u00adbank Bayern<\/strong> on the initia\u00adtive of the Bava\u00adrian state govern\u00adment. As the venture capi\u00adtal company of the Free State of Bava\u00adria, Bayern Kapi\u00adtal provi\u00addes equity capi\u00adtal to the foun\u00adders of inno\u00adva\u00adtive high-tech compa\u00adnies and young, inno\u00adva\u00adtive tech\u00adno\u00adlogy compa\u00adnies in Bava\u00adria. Bayern Kapi\u00adtal curr\u00adently mana\u00adges eleven invest\u00adment funds with an invest\u00adment volume of around 325 million euros. To date, Bayern Kapi\u00adtal has inves\u00adted around 290 million euros of venture capi\u00adtal in 265 inno\u00adva\u00adtive tech\u00adno\u00adlogy-orien\u00adted compa\u00adnies from a wide range of sectors, inclu\u00adding life scien\u00adces, soft\u00adware &amp; IT, mate\u00adri\u00adals &amp; new mate\u00adri\u00adals, nano\u00adtech\u00adno\u00adlogy and envi\u00adron\u00admen\u00adtal tech\u00adno\u00adlogy. As a result, more than 5,000 jobs have been perma\u00adnently crea\u00adted in Bava\u00adria in sustainable compa\u00adnies. www.bayernkapital.de<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Land\u00ads\u00adhu\u00ad\u00adt\u00ad\/\u00ad\u00adPlan\u00adegg-Martin\u00ads\u00adried\/ New York, April 17, 2019 \u2014 The Martin\u00ads\u00adried-based biophar\u00admaceu\u00adti\u00adcal company Immu\u00adnic Thera\u00adpeu\u00adtics (\u201cImmu\u00adnic\u201d) has successfully made the leap to the NASDAQ tech\u00adno\u00adlogy exch\u00adange in a so-called reverse take\u00adover. This is the first time that a port\u00adfo\u00adlio company of Wachs\u00adtums\u00adfonds Bayern, mana\u00adged by Bayern Kapi\u00adtal , has succee\u00added in going public. Toge\u00adther with a consortium&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42795,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42782","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-deals-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immunic Therapeutics: First NASDAQ listing - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunic Therapeutics: First NASDAQ listing - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Lands\u00adhu\u00adt\u00ad\/\u00adPlan\u00adegg-Martins\u00adried\/ New York, April 17, 2019 \u2014 The Martins\u00adried-based biophar\u00admaceu\u00adti\u00adcal company Immu\u00adnic Thera\u00adpeu\u00adtics (\u201cImmu\u00adnic\u201d) has successfully made the leap to the NASDAQ tech\u00adno\u00adlogy exch\u00adange in a so-called reverse take\u00adover. This is the first time that a port\u00adfo\u00adlio company of Wachs\u00adtums\u00adfonds Bayern, mana\u00adged by Bayern Kapi\u00adtal , has succee\u00added in going public. Toge\u00adther with a consor\u00adtium [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-29T21:59:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"284\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Immunic Therapeutics: First NASDAQ listing\",\"datePublished\":\"2019-04-29T21:59:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/\"},\"wordCount\":656,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/\",\"url\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/\",\"name\":\"Immunic Therapeutics: First NASDAQ listing - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg\",\"datePublished\":\"2019-04-29T21:59:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg\",\"width\":284,\"height\":284},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunic Therapeutics: First NASDAQ listing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunic Therapeutics: First NASDAQ listing - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/","og_locale":"en_US","og_type":"article","og_title":"Immunic Therapeutics: First NASDAQ listing - FYB Financial Yearbook","og_description":"Lands\u00adhu\u00adt\u00ad\/\u00adPlan\u00adegg-Martins\u00adried\/ New York, April 17, 2019 \u2014 The Martins\u00adried-based biophar\u00admaceu\u00adti\u00adcal company Immu\u00adnic Thera\u00adpeu\u00adtics (\u201cImmu\u00adnic\u201d) has successfully made the leap to the NASDAQ tech\u00adno\u00adlogy exch\u00adange in a so-called reverse take\u00adover. This is the first time that a port\u00adfo\u00adlio company of Wachs\u00adtums\u00adfonds Bayern, mana\u00adged by Bayern Kapi\u00adtal , has succee\u00added in going public. Toge\u00adther with a consor\u00adtium [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2019-04-29T21:59:52+00:00","og_image":[{"width":284,"height":284,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Immunic Therapeutics: First NASDAQ listing","datePublished":"2019-04-29T21:59:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/"},"wordCount":656,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/","url":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/","name":"Immunic Therapeutics: First NASDAQ listing - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg","datePublished":"2019-04-29T21:59:52+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/04\/a-bayern.jpg","width":284,"height":284},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/immunic-therapeutics-first-nasdaq-listing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Immunic Therapeutics: First NASDAQ listing"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42782"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42795"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}